1.中国中医科学院西苑医院,北京市海淀区西苑操场1号,100091
2.山西中医药大学
zhyq992@163.com
收稿:2023-07-13,
修回:2023-08-29,
纸质出版:2023-12-02
移动端阅览
董海航,蔡雨洁,王冬凌等.基于本虚标实之辨分期论治肝性骨病[J].中医杂志,2023,64(23):2471-2475.
DONG Haihang,CAI Yujie,WANG Dongling,et al.Treatment of Hepatic Osteodystrophy by Stages based on Root Deficiency and Branch Excess[J].Journal of Traditional Chinese Medicine,2023,64(23):2471-2475.
董海航,蔡雨洁,王冬凌等.基于本虚标实之辨分期论治肝性骨病[J].中医杂志,2023,64(23):2471-2475. DOI: 10.13288/j.11-2166/r.2023.23.017.
DONG Haihang,CAI Yujie,WANG Dongling,et al.Treatment of Hepatic Osteodystrophy by Stages based on Root Deficiency and Branch Excess[J].Journal of Traditional Chinese Medicine,2023,64(23):2471-2475. DOI: 10.13288/j.11-2166/r.2023.23.017.
肝性骨病当辨明本虚标实而分期论治。肝性骨病发病之本在肝、脾、肾三脏不足,而起病之标应分期而辨,隐匿期在少阳郁闭、枢机不利,发作期在浊毒瘀热、灼髓枯骨。治疗上当注重调补肝、脾、肾之虚损以培本筑基,隐匿期需注重畅达少阳肝胆之枢机以和调气血,发作期重在化瘀黜浊清源以利胆强骨,临床需根据个体症状增减用药,分清标本主次以紧扣病机,随证化裁,同时强调合理安全用药,保护肝脏功能。
Hepatic osteodystrophy (HO) should be treated by stages based on the differentiation of root deficiency and branch excess. The root cause of HO is the insufficiency of the liver, spleen, and kidney, and the branch onset should be differentiated by stages that in the incubation, the pathogenesis is
shaoyang
(少阳) constraint and block and cardinal disturbance, while in the attack period, it is turbid toxin, static heat, scorching marrow and withering bones. In treatment, attention should be paid to regulating and tonifying the depletion of the liver, spleen, and kidney to cultivate the foundation. In the incubation period, it is suggested to put focus on unblocking cardinal disturbance of
shaoyang
liver and gallbladder so as to regulate and harmonize
qi
and blood. In the attack period, the focus should be on dissolving stasis, removing turbidity, and clearing the source to promote gallbladder function and bone strength. In clinical practice, medication should be modified according to individual symptoms, and the root and the branch, the primary and the secondary should be differentiated to closely follow the pathogenesis and be tailored according to the symptoms. At the same time, reasonable and safe medication should be emphasized to protect liver function.
MONEGAL A , NAVASA M , PERIS P , et al . Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades? [J]. Calcif Tissue Int , 2013 , 93 ( 6 ): 571 - 576 .
European Association for the Study of the Liver . EASL clinical practice guidelines on nutrition in chronic liver disease [J]. J Hepatol , 2019 , 70 ( 1 ): 172 - 193 .
张文 , 陈姝延 , 吕婷婷 , 等 . 原发性胆汁性胆管炎合并骨质疏松症的诊断及处理 [J]. 临床肝胆病杂志 , 2021 , 37 ( 10 ): 2272 - 2276 .
RUDIC JS , GILJACA V , KRSTIC MN , et al . Bisphosphonates for osteoporosis in primary biliary cirrhosis [J]. Cochrane Database Syst Rev , 2011 ( 12 ): CD009144 . doi: 10.1002/14651858 http://dx.doi.org/10.1002/14651858 .
关茜 , 刘伟 , 陈佳美 , 等 . 扶正化瘀方治疗慢性肝病的临床与基础研究进展 [J]. 临床肝胆病杂志 , 2021 , 37 ( 6 ): 1449 - 1453 .
刘成海 , 赵志敏 , 吕靖 . 中医对肝纤维化逆转的认识与治疗 [J]. 临床肝胆病杂志 , 2019 , 35 ( 4 ): 728 - 733 .
杜丽坤 , 刘翠翠 , 刘春燕 . 从脾肾论治骨质疏松症 [J]. 辽宁中医药大学学报 , 2021 , 23 ( 6 ): 1 - 4 .
潘雪飞 , 邱蔚蔚 , 陈列虹 , 等 . 从肝性骨病探讨乙癸同源理论 [J]. 中国中医药科技 , 1994 ( 4 ): 12 - 14 .
BLACK DM , BAUER DC , VITTINGHOFF E , et al . Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials [J]. Lancet Diabetes Endocrinol , 2020 , 8 ( 8 ): 672 - 682 .
陈士铎 . 外经微言 [M]. 太原 : 山西科技出版社 , 2012 : 4 .
叶放 , 周静汶 , 皇金萍 , 等 . 肝硬化湿热瘀毒郁结复合病机的理论及临床应用研究 [J]. 南京中医药大学学报 , 2020 , 36 ( 6 ): 788 - 791 .
王宇 , 李爽 , 刘成海 . 基于《金匮要略》“血痹虚劳篇”探讨肝硬化“扶正化瘀”的中医论治思路 [J]. 上海中医药杂志 , 2023 , 57 ( 5 ): 1 - 3,7 .
黄正慧 , 徐雯洁 , 刘汶 . 基于文献数据挖掘技术的中医药治疗原发性胆汁性胆管炎用药规律 [J]. 北京中医药 , 2022 , 41 ( 7 ): 794 - 798 .
柳诗意 , 张引强 , 刘燕玲 , 等 . 不同活血化瘀法分阶段辨证干预乙肝肝纤维化的临床疗效研究 [J]. 中国中西医结合杂志 , 2013 , 33 ( 11 ): 1457 - 1461 .
章之琪 , 张晓朦 , 张冰 , 等 . 中药肝损伤风险分析与肝功能不全人群用药警戒思考 [J]. 中国药物警戒 , 2022 , 19 ( 6 ): 600 - 604 .
刘渡舟 , 程昭寰 . 肝病证治概要 [M]. 天津 : 天津科学技术出版社 , 1985 : 120 - 121 .
0
浏览量
5
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号